Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From Witty To Walmsley – The Priorities For GSK's New CEO

Executive Summary

It's Emma Walmsley's first week at the helm of GlaxoSmithKline. What can we expect in terms of her priorities?

You may also be interested in...



GSK Says Shingrix Shortage, Oncology Push Continues

GlaxoSmithKline said its increasingly streamlined operations are on a growth trajectory, but that capacity constraints mean demand for its popular shingles vaccine will keep outstripping supply.

Walmsley: GSK Will Take Incremental Deal-Making Approach In Building Up Oncology

GSK has more than doubled its oncology pipeline since July 2018, and the company's CEO thinks smaller deals and a new site combining R&D and manufacturing will enable its progress to continue.

J.P. Morgan Notebook Day 2: Walmsley On Diversity, Amgen's Overseas Cash, Growing Opdivo, Mylan On US Generic Pricing, Boston's Pipeline And J&J In Alzheimer's

Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: GSK's Walmsley looks to be a leader on diversity, Amgen talks tax reform and deals, Mylan raises the issue of generic drug shortages, Boston builds out its pipeline, and J&J is dealing in Alzheimer's disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1130496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel